Updates in CAR T-Cell Therapy and Bispecific Antibodies for the Treatment of Relapsed/Refractory Multiple Myeloma

Noa Biran, MD, and David Siegel, MD, review the shifting treatment paradigms in multiple myeloma (MM).

Experts on multiple myeloma discuss available BCMA-targeted CAR T-cell therapies and the KarMMa and CARTITUDE-1 clinical trials.

Noa Biran, MD, and David Siegel, MD, discuss how CAR T-cell availability has impacted the field of multiple myeloma.

Myeloma experts give an overview of allogeneic CAR T-cell therapy and other technology advances in MM.

A comprehensive discussion on bispecific antibodies and T-cell engagers in the treatment of multiple myeloma.

Noa Biran, MD, offers insights on ongoing research with bispecific antibodies in multiple myeloma.

Experts on multiple myeloma compare their treatment sequencing strategies.

Myeloma experts share their thoughts on the future of multiple myeloma treatment.

Nora Biran, MD, and David Siegel, MD, offer closing remarks on the MM treatment landscape.